|1.||Wang, Hai: 18 articles (05/2013 - 09/2004)|
|2.||Hu, Gang: 10 articles (09/2014 - 09/2004)|
|3.||Wang, Hong: 7 articles (08/2015 - 09/2004)|
|4.||Long, Chao-Liang: 5 articles (05/2013 - 03/2005)|
|5.||Zhang, Ying-Li: 5 articles (01/2007 - 01/2005)|
|6.||Xie, Weiping: 4 articles (11/2011 - 09/2004)|
|7.||Ding, Jian-Hua: 3 articles (09/2014 - 05/2005)|
|8.||Xie, Wei-Ping: 2 articles (08/2015 - 11/2012)|
|9.||Cui, Wen-Yu: 2 articles (05/2013 - 12/2008)|
|10.||Zhang, Yan-Fang: 2 articles (05/2013 - 12/2008)|
|1.||Hypertension (High Blood Pressure)
09/01/2010 - "Clinical trials of iptakalim in the treatment of mild-moderate hypertension have been completed in China. "
01/01/2007 - "Iptakalim is in phase II clinical trials now and has a promising future as a treatment for hypertension."
12/01/2011 - "These results demonstrate that iptakalim could protect against IR-induced endothelial dysfunction, and ameliorate IR associated with hypertension, possibly via restoring the balance between NO and ET-1 signaling."
12/01/2008 - "We hypothesized that iptakalim could prevent hypertension and retard the pathogenesis of endothelial dysfunction and renal injury in hyperuricemic rats. "
10/01/2005 - "[Renoprotective effect of iptakalim hydrochloride in hypertension]."
08/01/2015 - "Iptakalim significantly attenuated the increase in mean pulmonary artery pressure, RVSP, right ventricle to left ventricle plus septum ratio and small pulmonary artery wall remodeling in hypoxia-induced PAH rats. "
08/01/2015 - "Ninety-six Sprague-Dawley rats were placed into normobaric hypoxia chambers for four weeks and were treated with iptakalim (1.5 mg/kg/day) or saline for 28 days. "
11/01/2012 - "In hypoxia-induced animal models, iptakalim decreases the elevated mean pressure in pulmonary arteries, and attenuates remodeling in the right ventricle, pulmonary arteries and airways. "
11/01/2011 - "These results indicate that iptakalim inhibits PASMC proliferation and pulmonary vascular remodeling induced by hypoxia through downregulating the expression of PKC-α. "
11/01/2011 - "Iptakalim reduced hypoxia-induced expression of PKC-α, and abolished the effect of hypoxia on PASMC proliferation significantly in a dose-dependent manner in vitro. "
|3.||Pulmonary Hypertension (Ayerza Syndrome)
11/01/2011 - "Iptakalim can serve as a novel promising treatment for hypoxic pulmonary hypertension."
02/01/2008 - "This study provides further evidence that iptakalim may serve as another candidate drug to treat pulmonary hypertension."
03/28/2005 - "These findings suggest that iptakalim might be a promising candidate for the treatment of pulmonary arterial remodeling in pulmonary hypertension."
11/01/2011 - "In the present study, we found that iptakalim significantly decreased pulmonary artery pressure, inhibited pulmonary ariery remodeling and PKC-α overexpression in chronic hypoxia in a rat pulmonary hypertension model. "
01/01/2005 - "Hypoxic pulmonary hypertension (HPH) and iptakalim, a novel ATP-sensitive potassium channel opener targeting smaller arteries in hypertension."
09/01/2014 - "Iptakalim confers an antidepressant effect in a chronic mild stress model of depression through regulating neuro-inflammation and neurogenesis."
09/01/2014 - "Iptakalim (Ipt), an ATP-sensitive potassium (K-ATP) channel opener that can cross the blood-brain barrier freely, has been demonstrated to inhibit neuro-inflammation and enhance adult hippocampal neurogenesis. "
08/01/2015 - "The present study aimed to investigate the protective effects of iptakalim, an adenosine triphosphate (ATP)-sensitive potassium channel opener, on the inflammation of the pulmonary artery and endothelial cell injury in a hypoxia-induced pulmonary arterial hypertension (PAH) rat model. "
|5.||Brain Ischemia (Cerebral Ischemia)
06/01/2006 - "Global cerebral ischemia was induced by occluding the bilateral common carotid arteries in gerbils for 5 min. The open field maze and T-maze were employed to investigate the experimental therapeutic value of iptakalim on ischemic brain insult (n=8). "
06/01/2006 - "Iptakalim (0.5-4.0 mg/kg per day, ip) could reduce the high locomotor activity evoked by ischemia and improve global cerebral ischemia-induced working memory impairments. "
06/01/2006 - "Iptakalim plays a key role in preventing global cerebral ischemia-evoked insults in gerbils and glutamate-induced PC12 cell injury by anti-excitotoxicity. "
06/01/2006 - "Protective effects of iptakalim, a novel ATP-sensitive potassium channel opener, on global cerebral ischemia-evoked insult in gerbils."
10/01/2011 - "Iptakalim, an ATP-sensitive potassium channel opener, confers neuroprotection against cerebral ischemia/reperfusion injury in rats by protecting neurovascular unit cells."
|1.||Adenosine Triphosphate (ATP)
|2.||Potassium Channels (Potassium Channel)
|3.||Idiopathic pulmonary hypertension
|10.||Chemokine CCL2 (Monocyte Chemoattractant Protein 1)
|1.||Surgical Instruments (Clip)